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Leveraging Genetic Variability across Populations
for the Identification of Causal Variants
Noah Zaitlen,1,2,5 Bogdan Pasxaniuc,3,5 Tom Gur,1 Elad Ziv,4 and Eran Halperin1,2,3,*
Genome-wide association studies have been performed extensively in the last few years, resulting in many new discoveries of genomic
regions that are associated with complex traits. It is often the case that a SNP found to be associated with the condition is not the causal
SNP, but a proxy to it as a result of linkage disequilibrium. For the identiﬁcation of the actual causal SNP, ﬁne-mapping follow-up is per-
formed, either with the use of dense genotyping or by sequencing of the region. In either case, if the causal SNP is in high linkage disequi-
librium with other SNPs, the ﬁne-mapping procedure will require a very large sample size for the identiﬁcation of the causal SNP. Here,
we show that by leveraging genetic variability across populations, we signiﬁcantly increase the localization success rate (LSR) for a causal
SNP in a follow-up study that involvesmultiple populations as compared to a study that involves only one population. Thus, the average
power for detection of the causal variant will be higher in a joint analysis than that in studies inwhich only one population is analyzed at
a time. On the basis of this observation, we developed a framework to efﬁciently search for a follow-up study design: our framework
searches for the best combination of populations from a pool of available populations to maximize the LSR for detection of a causal
variant. This framework and its accompanying software can be used to considerably enhance the power of ﬁne-mapping studies.Introduction
Over the last several years, many genome-wide association
studies (GWAS) have been employed for the identiﬁcation
of hundreds of new genomic regions containing genetic
polymorphisms contributing to the risk of complex
human diseases. Each of these newly identiﬁed loci con-
tain dozens, sometimes even hundreds, of SNPs, few of
which are expected to play a functional role in altering
the disease status. Identifying these causal SNPs may
provide important insights into the biological basis of
complex human diseases, as well as offer diagnostic tools
that aid in treating patients and personalizing medicine.
Follow-up studies aim to identify the causal variants in
GWAS by more thoroughly examining the proximal
genetic variation of the associated locus. This examination
is usually done by a ﬁne-mapping approach in which the
genomic region is densely genotyped. Recent advances in
high-throughput sequencing technologies may lead, in
the next years, to follow-up studies that fully sequence
the associated region.
Amajor challenge currently facing the community is the
design of follow-up studies for the identiﬁcation of the
causal variant such that the power to distinguish the causal
variant from the neighboring SNPs is maximized. One of
the major obstacles complicating the design of such
studies is the local linkage disequilibrium (LD) structure
at the associated loci. In most cases, many of the SNPs in
these loci are in strong LD with one another because of
their physical proximity, and several of them are likely to
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The Astructure provides GWAS a powerful means of ﬁnding
new associations without directly genotyping the causal
variant, it also makes the identiﬁcation of the causal
variant a challenging task. Test statistics calculated in a
follow-up study over tightly linked SNPs will behave simi-
larly, and thus it is difﬁcult to distinguish between the
causal variant and its proxies.
In order to measure the ability of a follow-up study to
resolve the causal SNPs from those in strong LD, we intro-
duce a new metric called the localization success rate (LSR),
described in detail below. For these new metrics, consider
a follow-up study of a locus containing exactly two SNPs
that are in perfect LD, with only one being causal. If the
sample size and odds ratio are large, the study will have
a very high power to detect association; that is, the proba-
bility of ﬁnding a statistically signiﬁcant result will be
high. However, the LSR will only be 50%, because both
SNPs will have identical statistics. Given that a GWAS
has already identiﬁed the locus as having a signiﬁcant asso-
ciation, we are more interested in our new metric than in
power.
Traditionally, a follow-up study focuses the sequencing
and genotyping of an associated locus on individuals
from the original study population. This provides powerful
conﬁrmation of the original result, describes more pre-
cisely the set of polymorphisms in the region, and protects
against heterogeneous effects across populations. How-
ever, it is yet to be determined whether conducting
a follow-up study in the same population as that of the
original study provides the most powerful means of identi-
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attempted an alternative approach to this problem by con-
ducting follow-up studies over multiple populations.1,2
Leveraging the differences in local LD structure between
the populations may amplify the signal of the causal
variant, because SNPs strongly linked to the causal variant
in one population may not be strongly linked in another.
However, to date, it is not clear whether this approach is
useful in general. One may expect that always using a pop-
ulation with low average LD, such as an African popula-
tion, will result in the greatest LSR in distinguishing the
causal SNP from its neighbors.
In this work, we evaluate different strategies for ﬁne
mapping a region. We focus on ﬁne-mapping follow-up
studies in which signiﬁcant GWAS results have been
reported in a single population, because this is the most
common form of GWAS conducted so far. Speciﬁcally, we
develop an analytical framework for evaluating the LSR
of detection of a causal SNP in a region; our framework
takes into account the structure of the linkage disequilib-
rium in the studied population. Furthermore, we deter-
mine which population or set of populations achieves,
on average, an increase in LSR for ﬁne mapping. Surpris-
ingly, our results suggest that studies involving a mix of
two or three populations result in higher average LSRs
than do studies over a single population, even for cases
in which the single population is of higher genetic diver-
sity (e.g., an African population). Furthermore, we ﬁnd
that the optimal choice of populations varies from locus
to locus. Although we focus primarily on diseases in which
the causal variant has a ﬁxed effect across all populations
(as this is the case for the majority of diseases studied to
date3), we also propose a multistage method for addressing
diseases with heterogeneous effects across populations.
We incorporated our analytical framework into a soft-
ware package called MULTIPOP, which takes as an input
a set of regions, test statistics obtained for the SNPs in these
regions in previous studies of the phenotype (used as
priors), and a set of reference data sets from the available
populations. MULTIPOP uses this information to decide
how many samples of each population should be further
studied so that the LSR of detection of a causal SNP will
be maximized under budget constraints.Material and Methods
In a ﬁne-mapping follow-up study, individuals are genotyped or
sequenced at a set of loci that are shown to be associated with
the phenotype of interest in a previous GWAS. In this work, we
examine the question of whether the individuals selected for the
study should come from one or several populations and how
this choice affects the LSR of the causal variant from its linked
proxy SNPs. A direct approach to answering this question would
be to perform an extensive set of simulations of ﬁne-mapping
studies under a variety of disease models with reference data sets
such as the HapMap4 and to determine which study designs are
more powerful for causal-variant identiﬁcation. This approach,
although accurate, is prohibitively computationally expensive.24 The American Journal of Human Genetics 86, 23–33, January 8, 20As an alternative to this, we put forward the ideas of Han et al.5
and Conneely et al.,6 who use insightful statistical and algorithmic
observations to model the null and alternative distributions of
case control studies, providing a computationally feasible means
of studying multipopulation ﬁne-mapping studies. In addition,
we develop an analytical framework for designing new studies
over multiple populations, implemented in the software package
that we call MULTIPOP.
The multipopulation approach is based on the following intui-
tion: Suppose that in an initial study we identify several signiﬁcant
SNPs at a locus with one true causal variant; as observed by
Lawrence et al.7 Therefore, we are likely to ﬁnd more than one
signiﬁcant SNP in that region, because all SNPs linked to the causal
variant are potentially signiﬁcant. Consider a SNP strongly corre-
lated with the causal SNP (e.g., r2 > 0.9) and therefore highly
signiﬁcant. If we conduct a follow-up study in the same popula-
tion, the SNP will probably be signiﬁcant again. However, if we
select another population, in which the SNP is poorly correlated
to the causal SNP (e.g., r2 ¼ 0.1), then only the causal variant
will remain a strong candidate in the ﬁnal analysis. Built on this
intuition, our framework searches for the best combination of
populations to maximize the LSR for distinguishing the causal
variant among the tightly correlated SNPs in a region.
The challenge in implementing the above intuition is that the
correlation structure between the SNPs is based not merely on
two linked SNPs but on a complex correlation structure that
involves all SNPs in the region. To overcome this challenge, our
method uses a carefully chosen multivariate normal (MVN) distri-
bution to sample from the distribution of simulated case-control
studies over a region. That is, given the set of data that we would
use to simulate a study, our method computes the test statistics
over the simulated data without actually paying the computa-
tional cost of simulation. This strategymakes it feasible to estimate
the LSR of a study on the basis of themultidimensional correlation
structure. In addition, we use this framework to efﬁciently search
for an optimal study design in which there is freedom in the
choice of the studied population(s).Modeling LD by Using the MVN Distribution
We will ﬁrst describe how the MVN distribution can be used for
estimation of the LSR of detecting the causal SNP of a study
over one population. Consider an association study in which
we genotype a set of SNPs, s1, s2, ., sk, and measure their
frequency in N/2 cases, pþ1 , p
þ
1 , ., p
þ
k , and N/2 controls, p

1 ,
p2 , ., p

k , from the population. We can compute a statistic (the
Z score) for each SNP, Zi ¼
ﬃﬃﬃﬃ
N
p ðpþi  pi Þ=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2pið1 piÞ
p
, in which
pi ¼ (pþi þ pi )/2. Under the null hypothesis (the allele frequencies
in the cases and the controls are the same), this statistic is known
to be distributed according to a standard normal distribution.8
The alternative hypothesis is composite, depending on which
SNP is causal and its relative risk. Note that throughout this paper
we assume an additive model and that the term ‘‘relative risk’’
refers to the allelic relative risk. If we assume that SNP sc is the
causal SNP with a relative risk of gc, it is easy to calculate the
power of the test Zc under a signiﬁcance level of a. This power
can be calculated by noting that Zc  Nðlc
ﬃﬃﬃﬃ
N
p
,1Þ, in which the
noncentrality parameter is lc
ﬃﬃﬃﬃ
N
p ¼ ﬃﬃﬃﬃNp ðpþc  pc Þ= ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ2pcð1 pcÞp ,
which can be estimated given the relative risk and the minor
allele frequency (MAF) in the population. However, as a result
of linkage disequilibrium, other SNPs in the region may also
have a high power for association when this statistic is used.10
Particularly, it is well known9 that for a SNP sj with a correlation
coefﬁcient rcj with the causal c, Zj  ðlj
ﬃﬃﬃﬃ
N
p Þ, in which
lj
ﬃﬃﬃﬃ
N
p ¼ rjclc
ﬃﬃﬃﬃ
N
p
. In the extreme case that rcj ¼ 1, there is essen-
tially no distinction between statistics computed at sc and at
sj—the power of association may be high in both SNPs, but the
LSR for the causal SNP will be bounded by 0.5. It follows that
the LSR of the causal SNP in a region is a function of the allele
frequency of the causal SNP, the relative risk, the correlation struc-
ture in that region, and the study size.
One simple way of estimating the LSR is by simulation. We can
use a reference data set such as the HapMap4,10 to simulate
multiple case-control panels by specifying a causal variant, a rela-
tive risk, and a prevalence. There are various existing tools that
provide such simulations. In this work, we chose the widely
used software HapGen,11 which models the LD structure by using
the Li-Stephensmodel.12 For each such panel, we can calculate the
statistics Z1,., Zk and test whether the causal SNP turns out to be
the one with the largest statistic.
Although the simulation approachprovides accurate LSR estima-
tion, it is highly inefﬁcient. In our case, the large parameter space
for the study design (i.e., the number of individuals from each of
the populations), the causal SNP, and the relative risks make the
task of performing a simulation for eachpoint in that space compu-
tationally infeasible. We therefore add upon the observationmade
by Han et al.5 and Conneely et al.,6 who noticed that the distribu-
tion of Z ¼ Z1, Z2, ., Zk follows an MVN distribution
Z  NðL ﬃﬃﬃﬃNp ,SÞ, in which l ﬃﬃﬃﬃNp ¼ ðr1clc ﬃﬃﬃﬃNp ,r2clc ﬃﬃﬃﬃNp ,.,rkclc ﬃﬃﬃﬃNp Þ
and S is the k3 k variance-covariancematrix of the SNPs in which
the ith, jth entry of S is the correlation coefﬁcient of SNPs si, sj.
Given a region of the genome where the MAFs and correlations
of the SNPs are known, we can replace the simulation approach by
a simple Monte Carlo sampling from the corresponding MVN
distribution. Put differently, we draw samples directly from the
MVN distribution under the alternate hypothesis; each draw
corresponds to one round of simulation in which a case-control
panel has been created. We can now calculate the LSR as the top
statistic on the basis of these draws. We show in the Appendix
that this approach results in power estimates that are extremely
similar to the one calculated by the HapGen program.11 A similar
approach has been previously used to efﬁciently calculate the
power of an association study.5,6 Note, however, that in our case
the application is different because we consider the LSR, not the
power of association, for distinguishing the causal variant.
Furthermore, the use of multiple populations requires a different
MVN distribution than that described above.The MVN Distribution in Meta-Analysis
To extend the single-population MVN distribution to utilize infor-
mation from several studies over multiple populations, we must
ﬁrst select an appropriate statistical test. There exist many
methods for combining information across association studies,
(see Kavvoura and Ioannidis13 for a review). Here, we consider
the weighted Z score statistic,8 a commonly used meta-analysis
method.14
GivenM independent studies P1, P2,., PM, each of which geno-
types the SNPs s1, s2,., sk, let Zi, j be the Z score of SNP si in study
Pj. Each study has a vector of noncentrality parameters L1, L2,.,
LM, a variance-covariance matrix S1, S2,., SM, and a number of
individuals N1, N2, ., NM. For the sake of presentation, we will
assume that the studies are balanced (i.e., that there are the
same number of cases and controls), but the unbalanced caseThe Acan be easily incorporated into the framework. For SNP si we can
compute the weighted Z score statistic Ti ¼
P
j
ﬃﬃﬃﬃﬃ
Nj
p
Zi,j=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP
jNj
r
.
Because each Zi, j is normally distributed with a mean of li, j and
a variance of 1, Ti is also normally distributed, with a mean ofP
j
ﬃﬃﬃﬃﬃ
Nj
p
li,j
ﬃﬃﬃﬃﬃ
Nj
p
=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP
jNj
r
and a variance of 1. Therefore, the distribu-
tion of T ¼ (T1, T2, ., Tk) will also be MVN:
T  N
0
B@
P
j
ﬃﬃﬃﬃﬃ
Nj
p
Lj
ﬃﬃﬃﬃﬃ
Nj
p
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP
j Nj
q ,
P
j NjSjP
j Nj
1
CA: (Equation 1)
Because the covariance matrices are ﬁxed (they can be esti-
mated from the HapMap data set), the distribution T is deter-
mined by the study sizes, the causal SNP, the relative risk, and
the prevalence of the disease. For such a choice of parameters,
we can efﬁciently generate meta-analysis statistics drawn from
the alternative distribution for any locus by using a Monte Carlo
approach. We can draw random samples from T by using exist-
ing software packages (here we use the ‘‘mvtnorm’’ R package);
each draw from T is used as a replacement for simulating case-
control panels over each of the M populations and combining
their results with the meta-analysis statistic. We use this Monte
Carlo approach to examine the effectiveness of combining infor-
mation from distinct populations for identiﬁcation of the causal
variant. Intuitively, the optimal study design will consist of one
population with the lowest average LD; surprisingly, however,
we ﬁnd that for large sample sizes, a combination of a few
distinct populations yields the best LSR. (see Results section for
details).Optimizing Study Designs
A natural question arising from the above analysis is how one can
design a study that is optimized for detection of the causal variant
in a region. Given a set of loci that are the targets of ﬁne mapping
and a set of M populations available for genotyping, we are inter-
ested in choosing a number Ni for each population withPM
i¼1 Ni ¼ N, such that the meta-analysis study involving Ni cases
and controls from population i has the maximal LSR of detection
of the causal variant; the maximum is taken across all studies
involving N genotyped samples. To address this problem we
have developed an algorithm implemented in ourMULTIPOP soft-
ware that searches for the optimal study design, which we describe
next.
Once relative risks, prevalences, sample sizes, and causal vari-
ants are speciﬁed for each population, the MVN distribution in
Equation 1 gives the alternative distribution of the meta-analysis
statistic. Searching for the optimal study design is then reduced
to the problem of searching over the design parameters to identify
the design that maximizes the expected LSR. To perform such
a search, we need to have a prior distribution on the relative risk
of each SNP si in each population. This prior can be calculated
on the basis of the results of a previous association study; such
a study will provide the statistics Z*¼ (Z1*,., Zk*) for a given pop-
ulation. Z* ¼ (Z1*,., Zk*) are realizations of random variables Z ¼
(Z1, ., Zk) drawn from a MVN distribution. In this section, we
assume that the relative risks across multiple populations are the
same, and we later show how MULTIPOP can be adapted to
SNPs with heterogeneous effects. Under this ﬁxed-effects assump-
tion, we calculate a prior probability qi that SNP si is the causal SNP.
That is, we want to ﬁnd the maximum posterior probability qi ¼
Pr(si is causal j Z*). Following the intuition that SNPs with smallermerican Journal of Human Genetics 86, 23–33, January 8, 2010 25
p values are more likely to be causal, a naive way of estimating qi is
by setting qi ¼ jZi j=
Pk
j¼1 jZj j.
Although intuitive and easy to implement, the above approach
may be suboptimal because it completely ignores the correlation
structure in the region. We therefore implemented an alternative
approach that takes into account the statistic Z*, as well as the
correlation structure in the region. We use the original study to
calculate the empirical estimate of the relative risks g1, ., gk of
the SNPs in the region. If si is causal with a relative risk of gi,
then we can calculate the value li, in which li
ﬃﬃﬃﬃﬃ
N0
p
is the expected
noncentrality parameter of the statistic Zi and N
0 is the original
study size. Now, under the assumption that si is causal, Z* is
drawn from the MVN distribution Z  NðL ﬃﬃﬃﬃﬃN 0p ,SÞ, in which
l
ﬃﬃﬃﬃ
N
p ¼ ðr1ili
ﬃﬃﬃﬃﬃ
N 0
p
,.,rkili
ﬃﬃﬃﬃﬃ
N0
p Þ. For each SNP si, we compute qi, the
MVN probability density function of the observed Z scores Z*
under Z given that si is causal, and normalize these so that they
sum to 1. These q1, q2, ., qk serve as the prior probabilities that
each SNP is causal. Under various simulations, we ﬁnd that this
approach results in better LSR estimations (data not shown)
than do alternative estimates of qi.
Each study design D is speciﬁed by sample sizes (N1,., NM) for
each population, such that
PM
i¼1 Ni ¼ N. For a design D, we
compute the LSR bD, i given that SNP si is causal and has relative
risk gi, which is assumed to be known (gi is estimated from the
previous association study).We describe several differentmeasures
of LSR in the Results section. The expected LSR bD for the designD
is then estimated as the weighted sum of bD, i:
bD ¼
X
i
qibD,i:
Our method identiﬁes the best ﬁne-mapping study design by
using a grid-search algorithm over all possible designs D; this
grid search is feasible when the number of populations involved
is not too large. The ﬁnal design chosen is the D with the
maximum expected LSR out of all designs on the grid.Results
To examine the effects of using multiple populations on
the LSR for resolving a causal variant in a ﬁne-mapping
study, we performed extensive simulations over the
HapMap populations by using the MULTIPOP software
outlined above. We began by showing that the average
LSR is indeed increased when studies are designed with
multiple, as opposed to single, populations. Second, we
examined potential mechanisms for this improvement
by looking at the distribution of optimal designs. Third,
we investigated the effect that study design has on the
LSR and show that our proposed method attains close to
optimal LSR, outperforming designs that ignore the local
LD structure. Fourth, we explored an extension of our
method to handle SNPs with heterogeneous effects across
populations by using a multistage design. Finally, as a con-
crete example of the applicability of our approach, we used
existing breast cancer GWAS results to design a powerful
follow-up study over the HapMap populations.
For all our analyses, we used release 21 of the HapMap10
haplotype data for chromosome 1 over the CEU, YRI,
and ASN (JPTþCHB) populations. We randomly selected26 The American Journal of Human Genetics 86, 23–33, January 8, 2010,000 SNPs to serve as causal variants, and we created
a locus based on each of these SNPs by taking 20 additional
SNPs on each side of the selected causal variants. These loci
span 30 Kb on the average. The histogram of the MAFs of
the 10,000 randomly selected causal variants is displayed
in Figure S1 (available online), showing that the random
set of causal variants is sampled across all MAFs. We note
that these loci are not used for modeling one disease
with 10,000 causal variants but, rather, serve as a large
set for assessing the expected behavior of our methods
across the genome. For each of these 10,000 loci, on the
basis of the HapMap data, we computed a correlation
matrix S used in the meta MVN described in the Material
and Methods section. These simulated loci served as the
starting point for each of the experiments described in
this section. In the Appendix, we show that very similar
results can be obtained by simulating the data sets with
the use of HapGen.11 A prevalence of 0.01 is used
throughout this section.
LSR Metrics
Currently, there is no widely accepted measure of power
for identifying the causal SNP (ﬁne-mapping power), so
we start by giving a precise deﬁnition of how we measure
the LSR for the causal variant from its neighboring SNPs
in this work. We propose two correlated measures, each
of which may be useful depending on the study objective;
both measures can be easily calculated by using samples
drawn from the meta MVN.
The ﬁrst measure of LSR computes the fraction of study
samples in which the causal variant has the lowest p value
among all SNPs in the region. This corresponds to the
scenario in which exactly one SNP from each region is
undergoing functional analysis; we therefore measure the
fraction of regions in which the actual causal variant will
be chosen for the functional analysis. The second measure
that we use is the average rank of the causal variant when
the SNPs are ordered from lowest to highest p value with
ties broken randomly. Although this is not ameasure of the
probability of an event, and thus not ameasure of power in
the usual statistical sense, it can be thought of as the
expected number of SNPs that will have to undergo func-
tional analysis before the causal variant is isolated. Because
it is likely that statistical rank will prioritize functional
analysis, this measure is a useful way of examining ﬁne-
mapping results.
The suggested measures do not quantify the precision of
the estimates of the probability that SNP is causal (qi, as
described in the Material and Methods section). Instead,
given such probabilities, or any other statistic, they aim
at measuring the potential success of a follow-up study in
which, for example, functional analysis will be performed
on a smaller number of SNPs. Although the proposed
measures are correlated, they are not always optimized by
the same choice of populations, and therefore an investi-
gator should decide which measure to use on the basis of
his or her plans for a follow-up study. Note that each of10
Figure 1. The Average Rank of the Causal Variant in 10,000
Simulated Loci, with 3000 Cases, 3000 Controls, and g ¼ 1.4 for
Seven Different Study Designs
Designs over multiple populations, such as the CEUþYRI, split
individuals evenly among them. Using multiple populations
reduces the number of functional assays expected before the
causal variant is identiﬁed.
Figure 2. The Fraction of Times that a Design Achieves the
Maximal LSR for Each of the Study Designs
The statistics are based on 10,000 simulated loci, with 3000 cases,
3000 controls, and g ¼ 1.4. As expected, the YRI population is
most often the best choice for study design. However, it is the
top choice only 44% of the time. The combination of all three
populations is almost never the best study design, accounting
for only 2.6% of the 10,000 designs. Interestingly, it maximizes
the average LSR, suggesting, ﬁrst, that it protects against the vari-
ance of different local LD structures and, second, that tailoring
study designs to the loci in the follow-up study is beneﬁcial.these measures are calculated in a trivial manner once
samples from the alternative MVN distribution are gener-
ated. Both measures are applied only to SNPs exceeding
a speciﬁed signiﬁcance level, and the sample sizes used in
our simulations provided enough power that the causal
variant had a p value % 0.05 more than 98% of the time.Balanced Multiple-Population Studies
To demonstrate the beneﬁt of using multiple populations,
we ﬁrst examined the simple approach of dividing individ-
uals evenly among the HapMap populations in compar-
ison to using all individuals in each population in isola-
tion. For example, the YRIþCEU study uses the same
number of YRI and CEU samples, whereas the CEU study
includes only CEU samples.
Figure 1 presents the estimated LSR of seven different
balanced study designs, clearly showing that there is an
increase in the LSR of identifying the causal variant
when multiple populations are used. The average rank of
the causal variant decreases from 3.40, when the study is
performed only on the ASN population, to 1.94, when
the study design involves all three populations. To date,
most GWAS have been performed in one population,
usually a population of European ancestry similar to the
CEU population in the HapMap. As shown in Figure 1,
studies that combine CEU individuals with individuals
from YRI or ASN populations achieve higher LSRs (i.e.,
a signiﬁcant reduction in the average rank of the causal
SNP). Furthermore, study designs that involve a combina-
tion of populations result in higher LSRs than do studies
involving one population alone, even when compared to
the YRI population.
The above result is surprising, given that intuition leads
us to believe that performing a study in a single population
with the lowest average LD in the ﬁne-mapping regionThe Ashould yield the greatest LSR. Figure 2 shows that this intu-
ition is indeed correct. If we consider one genomic region
at a time, in the vast majority of cases, studies involving
exactly one of the populations will result in better ﬁne-
mapping power than will studies involving a combination
of populations. In particular, for most genomic regions,
the YRI studies yield the greatest LSR. This is intuitive,
because it is expected that in most cases two SNPs that
are in high LD in an African population will also be in
high LD in other populations, such as populations of Euro-
pean ancestry.
At ﬁrst glance, the conclusions of Figure 1 and Figure 2
may seem contradictory. However, because the population
that maximizes the ﬁne-mapping LSR differs across
different regions, studies that involve more than one pop-
ulation essentially achieve a high average LSR, when the
average is taken across all studied regions. Put differently,
there is a higher variance across regions in which the
optimal LSR is achieved by one population alone, and
therefore a combination of two or more populations yields
a better average LSR.
Other choices of the sample sizes, relative risks, and
measures of LSR resulted in a similar trend. For example,
Figure 3 shows the change in LSR for CEU, ASN, CEUþ
ASN, as well as relative risks 1.1 to 1.9 and a ﬁxed sample
size of 1000 cases and 1000 controls. The trend observed
in Figure 2 for g¼ 1.4 extends to any considered g. Designs
across both of the populations outperform each popula-
tion in isolation. However, as the relative risk increases,
there are diminishing returns in using multiple popula-
tions as compared to using single populations. We believe
that this is because even SNPs with relatively strong r2 aremerican Journal of Human Genetics 86, 23–33, January 8, 2010 27
Figure 3. Histogram of the Average Rank of the
Causal Variant in 10,000 Simulated Loci, with 1000
Cases, 1000 Controls, and a Relative Risk of 1.4 for
Three Different Study Designs over a Range of Rela-
tive Risks
The study designs are all CEU, all ASN, and CEU-
þASN. CEUþASN designs have individuals split
evenly between them. The trend observed in the
simple designs is preserved across relative risks.easily distinguished at high relative risks. On the other
hand, SNPs with very strong signals are very tightly corre-
lated in both CEU and ASN in that they cannot be distin-
guished with the current sample size (or at all, in the case
of perfect LD).
Designing Multiple-Population Studies
The results presented above illustrate the effectiveness of
using multiple populations in ﬁne-mapping studies. How-
ever, given a ﬁxed budget of N individuals, an uneven split
of individuals across thepopulationsmayprovide increased
LSR of the causal variant. Furthermore, as the name sug-
gests, ﬁne-mapping follow-up studies are generally based
on results of previous GWAS, and incorporating this prior
informationmay lead to better resolution of the causal SNP.
To examine this scenario, we began by simulating a study
made up of 1000 cases and 1000 controls in one of the
HapMap populations. We then quantiﬁed the LSR increase
when additional individuals from various populations
were added to the study. To assess the gain in LSR due to
multiple populations, we also used combinations of popu-
lations not contained in the original study. For each of
these designs, we computed the LSR over each of the
10,000 simulated loci and plotted the average LSR. The
results are shown in Figure 4 and Figure 5.
The study designs withmultiple populations have signif-
icantly better LSRs across a range of sample sizes, with the
beneﬁt more pronounced in smaller studies. As the sample
size grows, the variance of test statistics decrease, so that
closely linked SNPs are more easily distinguished even in
one population. Notice that the combination of CEU and
YRI outperforms the designs across all three populations
until sample sizes are very large, at which point the use
of all populations becomes more successful. This demon-
strates the importance of carefully selecting the popula-
tions to be used in the study as opposed to simply
including as many different populations as possible.
It is intriguing to understand the limits of such an
approach. To do this, we compared the different study
designs with a hypothetical design in which the optimal
population was used for each region. Note that no method28 The American Journal of Human Genetics 86, 23–33, January 8, 2010could ever achieve such LSR, because we are
using different study designs for different
regions; however, this hypothetical design is
still useful and serves here as an upper bound
on the possible LSR that one can achieve.Using our MULTIPOP method described above, we
selected a population or combination of populations
from among those described in the previous paragraph.
The results are also shown in Figure 4 and Figure 5.
Although our method is not as successful as the hypothet-
ical optimal design, it clearly outperforms a naive selection
of a single type of population. The fact that there is a clear
difference between choosing the best populations at every
locus and using the combination of all three populations
indicates that there is large variance in the performance
of a study that is based on any particular population.
Furthermore, the variance of the MULTIPOP approach is
much lower than even that of the multipopulation
approach (data not shown). Thus, it improves the average
LSR while still protecting against regions with very poor
performance in a particular population.
Implications for Sequencing-Based Studies
Many future follow-up studies are expected to use sequenc-
ing technologies for the ﬁne-mapping stage. Particularly,
a possible strategy is a multistage study in which the ﬁrst
stage consists of the sequencing of a small number of indi-
viduals and the second stage consists of the genotyping of
a set of SNPs discovered in the ﬁrst stage across a larger
population. This is, for example, similar to the procedure
followed by Udler et al.1 It is therefore of interest to discuss
our ﬁndings in the context of more dense genotyping data
that result from such sequencing studies.
For this purpose, we simulated 1000 regions from the ten
ENCODE regions that were thoroughly resequenced in the
HapMap populations.15 Each of the 1000 regions contains
81 SNPs spanning 18 Kb on average (40 SNPs at each side of
the causal SNP), as opposed to 41 SNPs that were used in
the previous experiment. We used a wider window because
the SNPs in the ENCODE region are more densely geno-
typed. For each of these regions, we computed the LSR at
a relative risk of 1.4.
Figure 6 shows the results for the ENCODE regions and
for random HapMap regions for the same study designs.
Although the ENCODE regions have lower LSRs than do
random regions, the same trends in terms of study design
Number of additional samples added to a 2000 case/control CEU data set.
Number of additional samples added to a 2000 case/control CEU data set.
Figure 4. Average Rank and Fraction of Time that
a Causal Variant Has the Best Statistics in Follow-
Up Studies over 10,000 Simulated Loci with a Rela-
tive Risk of 1.4
The designs include 1000 cases and 1000 controls
from the CEU data set combined with x cases and
controls taken from CEU, YRI, ASN, and ASN þ
YRI, where x ranges from 0 to 10,000 in steps of
500. For the studies involving YRIþASN designs,
the same number of samples is taken from both
YRI and ASN. The hypothetical optimal method is
choosing the optimal design in each of the 10,000
designs, and MULTIPOP uses the populations pre-
dicted by our algorithm (see Material and Methods)
as having the maximal LSR.are still observed. That is, the use of multiple populations
improves the LSR of identiﬁcation of the causal variant
regardless of the SNP density in the regions targeted for
ﬁne mapping.
Causal Variants with Heterogeneous Effects
Although the majority of causal variants have a ﬁxed effect
size across all populations,3 a signiﬁcant percentage will
show a heterogeneous effect across different populations.
In this case, a naive implementation of our proposed
approach will incorrectly use an estimated relative risk
from only a single population; namely, the population in
which the initial GWAS was performed. In order to address
this situation, we propose a multistage design in which an
initial sample is taken from each of the available popula-
tions and used for estimating the relative risks for each
population and these estimates are then plugged into our
proposed framework in the design of the next stage.
To explore the effectiveness of such an approach, we
simulated 3000 case and 3000 control data sets with rela-The American Journtive risks 1.1, 1.3, and 1.6 for the ASN, YRI,
and CEU data, respectively. We assessed the
LSR when each population was used indepen-
dently in a multistage design in which 1500
cases and 1500 controls (500 cases and 500
controls from each population) were geno-
typed in the ﬁrst stage. The accuracy of the esti-
mate of the relative risk from the ﬁrst stage is
function of the MAF, the true relative risk,
and the sample size. Choosing the optimal
number of individuals for each stage is an
interesting problem beyond the scope of this
work. We then plugged the results for the ﬁrst
stage into the MULTIPOP framework to deter-
mine a powerful design for the remaining
1500 cases and 1500 controls by searching
over all balanced combinations of samples
from the three populations. The results are pre-
sented in Figure 7. The ASN sample performed
poorly because it was underpowered for a rela-
tive risk of only 1.1. Themultistage MULTIPOP
method outperformed the single populationseven in the presence of heterogeneous effect sizes. Despite
its low relative risk, the ASN population is still beneﬁcial in
many loci. The CEU, YRI, CEUþYRI, and ASNþCEUþYRI
data were optimal in 34%, 36%, 25%, and 5% of the
10,000 loci, respectively, demonstrating that in 5% of the
loci, the addition of ASN individuals increased the LSR.
Sample Designs for Breast Cancer
To provide a concrete example of the applicability of our
approach, we used MULTIPOP to design a follow-up study
based on published results from breast cancer GWAS.2,16–19
We assumed a total budget of 6000 individuals and access
to case-control groups in all of the three HapMap popula-
tions: CEU, YRI, and ASN. For each of the published
SNPs (rs11249433, rs1219648, rs13387042, rs2046210,
rs2107425, rs2180341, rs2981582, rs3803662, rs3817198,
rs4415084, rs8051542, and rs999737), we took a window
of 81 SNPs and extracted the corresponding haplotypes
for the unrelated HapMap individuals in all three popula-
tions. We used the expected Z scores given the publishedal of Human Genetics 86, 23–33, January 8, 2010 29
Number of additional samples added to a 2000 case/control YRI data set.
Number of additional samples added to a 2000 case/control YRI data set.
Figure 5. Average Rank and Fraction of Time that
a Causal Variant Has the Best Statistics in Follow-
Up Studies over 10,000 Simulated Loci with a Rela-
tive Risk of 1.4
The designs include 1000 cases and 1000 controls
from the YRI data set combined with x cases and
controls taken from CEU, YRI, ASN, and ASN þ
CEU, where x ranges from 0 to 10,000 in steps of
500. For the studies involving CEUþASN designs,
the same number of samples is taken from CEU
and ASN. The hypothetical optimal method is
choosing the optimal design in each of the 10,000
regions, and MULTIPOP uses the populations pre-
dicted by our algorithm (see Material and Methods)
as having the maximal LSR.odds ratios and the pairwise LD estimated from the CEU
HapMap populations. Unfortunately, only the most signif-
icant odds ratios and Z scores are publicly available. InFigure 6. Histogram of the Average Rank of the Causal Variant in 1000 ENCODE
of 1000 Cases and 1000 Controls and a Relative Risk of 1.4
Seven designs over different combinations of the HapMap populations were exami
multiple populations improved the LSR of identifying the causal variant.
30 The American Journal of Human Genetics 86, 23–33, January 8, 2010practice, we recommend using the Z scores
for all of the SNPs as priors, imputing those
that are missing from the study. For this
reason, it is possible that the following designs
could be further improved with the use of addi-
tional data from the original studies.
MULTIPOP explored all designs over subsets
of the three populations, with a total size of
3000 cases and 3000 controls and a grid
interval of 200 individuals. For each of the
designs, we computed the expected average
rank of the causal variants by integrating over
each SNP in the considered windows, using
the expected Z scores to compute priors (as
described in detail above). As in the simulation
studies, the optimal design varied widely from
region to region, one population generally out-
performing the others in terms of estimated
LSR. However, as in our previous simulations,
the overall most successful estimated designis a mixture of 600 CEU, 2800 YRI, and 2600 ASN individ-
uals. Many other similar designs were close in expected
LSR, so we believe that the grid interval was sufﬁcientlyRegions and 1000 HapMap Regions for a Study Size
ned. In both random and ENCODE regions, the use of
Figure 7. Average Rank of the Causal Variant in 10,000 Simu-
lated Loci with 3000 Cases, 3000 Controls, and Relative Risks of
1.1, 1.3, and 1.6 for ASN, YRI, and CEU, Respectively
Four study designs were considered: all ASN, all CEU, all YRI, and
a multistage design using our MULTIPOP algorithm and designed
to address the issue of heterogeneous effects in different popula-
tions. Despite an initial stage requiring genotyping of 1000 ASN
individuals, our algorithm still outperformed single-population
designs.granular. The most successful designs for the different loci
as found by MULTIPOP are displayed in Table S1.Discussion
Discovering causal variants through ﬁne-mapping follow-
up studies is one of the fundamental challenges facing
the genetics community today. Although the list of novel
loci associated with complex phenotypes is growing
quickly, the precise variants altering function are not as
forthcoming. As discussed in Lawrence et al.,7 the problem
of genetically indistinguishable SNPs, in which two associ-
ated SNPs are in perfect LD, makes the problem of causal
detection particularly challenging.
In this work, we challenge the intuitive assumption by
which a study consisting of a single homogeneous popu-
lation with a maximum genetic diversity is always the
optimal strategy, particularly in the context of the ﬁne-
mapping stage. As opposed to this intuition, we show
that the LSR of a causal variant increases consistently
when multiple distant populations are genotyped in the
follow-up study. One possible explanation for this phe-
nomenon is that a combination of differences in LD struc-
tures among the populations results in a more robust
strategy for ﬁne mapping; indeed, we show that for every
speciﬁc locus, the strategy involving multiple populations
is rarely optimal but that when averaging across multiple
loci, the strategy consistently provides improved LSR.
For the above reason, we do not advocate a general
strategy of choosing many diverse populations when con-
ducting ﬁnemapping. Each study is different, and for some
studies the optimal strategy will indeed consist of genotyp-The Aing just a single population. As we show here, the optimal
strategy depends on the speciﬁc loci, the relative risks, and
the number of individuals to be genotyped. To this end, we
have created a software package called MULTIPOP to aid
researchers in choosing a successful design.
It is important to realize that the results demonstrated
here by no means cover all possible scenarios of follow-
up studies. Particularly, our analysis corresponds to an
additive disease model with one causal SNP, and we treat
one speciﬁc meta-analysis statistic. Any deviation from
this scenario requires another similar analysis. Thus,
researchers who are interested in using a different statistic,
testing a different hypothesis (e.g., that the disease follows
a dominance model and not an additive one), or opti-
mizing a different metric for power are recommended to
perform a set of simulations based on the framework
suggested here. Furthermore, error in the variance-covari-
ance matrix as a result of a ﬁnite reference sample size,20
as well as errors in the estimation of the relative risk,
such as those from the winner’s curse, might disturb the
accuracy of the LSR estimates in MULTIPOP and, hence,
the ﬁnal design choices. The simulated data sets used in
this work were based on the HapMap genotypes. As more
sequence and denser genotype databases are becoming
available (e.g., the 1000 Genomes Project21), these esti-
mates will bemore andmore accurate and, thus, the choice
of the study design will come closer and closer to the
optimum.Appendix
Accuracy of Meta-Analysis MVN Distribution
We assess the accuracy of the meta-analysis MVN distribu-
tion framework by comparing it to HapGen,11 a widely
used and accepted method of simulating case-control
panels. We randomly selected 1000 SNPs from chromo-
some 1 to serve as causal variants and took a window of
40 SNPs (20 downstream and 20 upstream of the causal
SNP) to simulate 1000 loci for ﬁnemapping. For each locus
and each population, we used HapGen to generate 1000
case-control panels of 1000 cases and 1000 controls, each
with a relative risk of 1.4. We compared the mean c2, the
average rank of the causal variant, and the fraction of
noncausal SNPs with p values below 0.05 in this simulated
data to results drawn from the MVN distribution for
each locus by using MULTIPOP. For designs with multiple
populations, we used the weighted sum of the Z score
meta-analysis statistic to combine the data from each pop-
ulation. In addition, we compared the measures of effec-
tiveness described above over the simulated and MVN-
distribution-generated data. As shown in Table 1, the
statistics estimated from the simulated data are very similar
to those from the MVN distribution. There is a slight
increase in themeasures of LSR from the empirically gener-
ated data from HapGen. We believe that this is due to
weaker correlation in the HapGen-generated data. Eachmerican Journal of Human Genetics 86, 23–33, January 8, 2010 31
Table 1. Comparison between MVN and HapGen on Various
Measures, Showing the Tight Correlation between the Results
Obtained by MULTIPOP and those Obtained with the HapGen
Method
c2 Avg. Rank FP Rate
Design HapGen MVN HapGen MVN HapGen MVN
CEU 20.41 20.42 2.55 3.23 0.32 0.32
ASN 19.64 19.62 2.76 3.42 0.30 0.30
YRI 19.48 19.48 2.17 2.46 0.27 0.27
CEUþASN 35.53 37.11 1.71 2.00 0.39 0.37
CEUþYRI 34.58 36.82 1.30 1.29 0.38 0.36
YRIþASN 33.85 35.87 1.16 1.24 0.37 0.34
CEUþYRIþASN 49.37 53.36 1.01 0.98 0.43 0.39
c2 is the average c2 value of the causal variant. Avg. Rank is the average rank of
the causal variant. FP Rate is the average fraction of noncausal SNPs with
p values below 0.05. The slight differences are most likely due to the modeling
of recombination events in HapGen that break the LD structure.recombination event in the Li-Stephens model will reduce
the correlation and thereby improve the LSR of ﬁne
mapping.Supplemental Data
Supplemental Data include one ﬁgure and one table and can be
found with this article online at http://www.ajhg.org.Acknowledgments
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